Biofrontera (NASDAQ:BFRI – Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Biofrontera to post earnings of ($0.07) per share and revenue of $14.53 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Biofrontera Price Performance
Shares of NASDAQ BFRI opened at $0.87 on Wednesday. Biofrontera has a 1-year low of $0.65 and a 1-year high of $2.43. The business’s fifty day moving average price is $1.07 and its two-hundred day moving average price is $1.04. The firm has a market capitalization of $6.78 million, a PE ratio of -0.39 and a beta of 0.30.
Analyst Upgrades and Downgrades
Separately, Benchmark reaffirmed a “buy” rating and issued a $7.00 target price on shares of Biofrontera in a research report on Friday, November 15th.
About Biofrontera
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
Further Reading
- Five stocks we like better than Biofrontera
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- What Are the U.K. Market Holidays? How to Invest and Trade
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
